Generic Drug Manufacturer Liability: Achieving a Balance Between Consumer Affordability and Safety.
- Published in:
- Journal of Corporation Law, 2012, v. 38, n. 1, p. 177
- By:
- Publication type:
- Article
Works matching DE "PLIVA v. Mensing (Supreme Court case)"
Results: 5
1
2
12 ANGRY MEN V. THE AGENCY: WHY PREEMPTION SHOULD RESOLVE THIS CONFLICT IN DRUG LABELING LITIGATION.
- Published in:
- Marquette Law Review, 2017, v. 100, n. 4, p. 1309
- By:
- Publication type:
- Article
3
Post PLIVA v. Mensing liability for generic medicine manufacturers: Food and Drug Administration to propose rule changes creating parity between generic and brand-name medicine manufacturers.
- Published in:
- Journal of Generic Medicines, 2013, v. 10, n. 3/4, p. 230, doi. 10.1177/1741134314553224
- By:
- Publication type:
- Article
4
THE IMPLICATIONS OF THE SUPREME COURT'S DECISION REGARDING LABELING AND LIABILITY OF GENERIC DRUGS.
- Published in:
- Thomas Jefferson Law Review, 2012, v. 35, n. 1, p. 45
- By:
- Publication type:
- Article
5
PRODUCTS LIABILITY--CONFLICT PREEMPTION: REWRITING THE TEST FOR IMPOSSIBILITY: THE UNITED STATES SUPREME COURT REMOVES THE PROTECTION OF THE LAW FOR GENERIC DRUG RECIPIENTS PLIVA, Inc. v. Mensing, 131 S. CT. 2567 (2011).
- Published in:
- North Dakota Law Review, 2011, v. 87, n. 3, p. 355
- By:
- Publication type:
- Article